Ignite Creation Date:
2025-12-24 @ 3:52 PM
Ignite Modification Date:
2025-12-24 @ 3:52 PM
Study NCT ID:
NCT05280392
Status:
TERMINATED
Last Update Posted:
2023-05-15
First Post:
2022-02-11
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Expectation, Motivation and Experience of HIV-patients Regarding Participation to an HIV Cure-related Clinical Trial
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006679', 'term': 'HIV Seropositivity'}], 'ancestors': [{'id': 'D015658', 'term': 'HIV Infections'}, {'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D015229', 'term': 'Sexually Transmitted Diseases, Viral'}, {'id': 'D012749', 'term': 'Sexually Transmitted Diseases'}, {'id': 'D016180', 'term': 'Lentivirus Infections'}, {'id': 'D012192', 'term': 'Retroviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D007153', 'term': 'Immunologic Deficiency Syndromes'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'OTHER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 6}, 'patientRegistry': False}, 'statusModule': {'whyStopped': 'EHVA T02/ANRS VRI07 clinical trial had been discontinued. Find relevant information on the EHVA website: https://ehv-a.eu/trials/ehva-t02', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2022-06-21', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-05', 'completionDateStruct': {'date': '2023-03-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-05-11', 'studyFirstSubmitDate': '2022-02-11', 'studyFirstSubmitQcDate': '2022-03-14', 'lastUpdatePostDateStruct': {'date': '2023-05-15', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-03-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-03-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of patients satisfied with their participation and the associated factors', 'timeFrame': 'through study completion, an average of 1 year', 'description': "Through statistical analyses of some self-administered questionnaires items we will highlight the participants' satisfaction and experience of the participation."}, {'measure': 'Impact of the participation in the trial on participant quality of life and quality of sexual life', 'timeFrame': 'through study completion, an average of 1 year', 'description': 'Through statistical analyses of some self-administered questionnaires items (in particular the SF12.v2 scale for quality of life) and thematic analyses of semi-directive individual interviews we will highlight the impact of the participation in the trial.'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['HIV cure-related clinical trials', "Participants' expectations and experiences"], 'conditions': ['HIV Seropositivity']}, 'descriptionModule': {'briefSummary': 'Following the ANRS-APSEC survey, AMEP-EHVA T02 is a longitudinal social science study that will explore the experience of people living with HIV (PLWH) who were offered to participate in the European randomized phase II placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine including antiretroviral treatment interruption (EHVA T02/ANRS VRI07).', 'detailedDescription': 'Moving towards the discovery of an HIV cure is of major public health interest, not only for people living with HIV (PLWH) who currently must take lifelong antiretroviral treatment (ART), with its associated side effects and comorbidities, but also for the community as a whole. An HIV cure will end the virus transmission, lead to global care-related savings and decrease in HIV-related stigma.\n\nThe present longitudinal social science study concerns the experience of PLWH who were offered to participate in the European randomized phase II placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine including ART treatment interruption (EHVA T02/ANRS VRI07).\n\nThe objectives are to document:\n\n1. the evolution over time of expectations and motivations related to participation in the trial,\n2. anticipation and understanding of risks and benefits related to participation,\n3. evolution over time of participation experience and of satisfaction with the information delivered,\n4. experience and perception of the ATI period and its impact on preventive behaviours and sexual quality of life,\n5. motivations and experience related to refusal of participation, or if any, related to non-inclusion because of negative screening results.\n\nThis international multicentre longitudinal study will be nested within the EHVA T02/ANRS VRI07 trial, and will comprise two components. A quantitative component designed to answer to the four first objectives, and a qualitative one that will retrospectively deepen the trial participation experience and will also document the motivation for participation refusal and the experience of participants not included because of negative screening results (objective 5). The quantitative survey will be conducted within participating centres that estimate to include at least 5 participants, and the qualitative one only in France for feasibility purpose.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'The quantitative survey will be proposed to all the PLWH included in the EHVA T02/ANRS VRI07 trial (except in germany where the center estimates to include less than 5 participants)(n = 69 max), the inclusion criteria being those defined by the clinical protocol.\n\nParticipants to the qualitative survey will be recruted in the three EHVA T02/ANRS VRI07 French centers.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* people living with HIV\n* who were offered to participate in EHVA T02 clinical trial'}, 'identificationModule': {'nctId': 'NCT05280392', 'acronym': 'AMEP-EHVA T02', 'briefTitle': 'Expectation, Motivation and Experience of HIV-patients Regarding Participation to an HIV Cure-related Clinical Trial', 'organization': {'class': 'OTHER_GOV', 'fullName': 'ANRS, Emerging Infectious Diseases'}, 'officialTitle': 'Expectation, Motivation and Experience of HIV-patients Regarding Participation to the EHVA T02/ANRS VRI 07 HIV Cure-related Clinical Trial (AMEP-EHVA T02)', 'orgStudyIdInfo': {'id': 'ANRS 95052'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'People living with HIV', 'description': 'PLWH who were offered to participate in the EHVA T02/ANRS VRI07 clinical trial', 'interventionNames': ['Other: Self-administered questionnaires', 'Other: Semi-directive individual interviews']}], 'interventions': [{'name': 'Self-administered questionnaires', 'type': 'OTHER', 'description': '4 self-questionnaires given to EHVA T02 participants: at inclusion (Q1, week 0), at the beginning of the ATI period (Q2, week 18), at the end of the ATI period (Q3, date depending on the participant) and at the end of the follow-up period of the clinical trial (Q4, week 54 at the latest)', 'armGroupLabels': ['People living with HIV']}, {'name': 'Semi-directive individual interviews', 'type': 'OTHER', 'description': 'With EHVA T02 participants (n=10 to 15): at the end of the follow-up period of the clinical trial.', 'armGroupLabels': ['People living with HIV']}, {'name': 'Semi-directive individual interviews', 'type': 'OTHER', 'description': 'With patients who refused to participate to EHVA T02 or patients not included because of negative screening results (n=10 to 15): within 21 days after the refusal or the results of the screening', 'armGroupLabels': ['People living with HIV']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Lausanne', 'country': 'Switzerland', 'facility': 'CHUV', 'geoPoint': {'lat': 46.516, 'lon': 6.63282}}], 'overallOfficials': [{'name': 'Christel Protiere, Dr', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Institut National de la Santé Et de la Recherche Médicale, UMR1252 SESSTIM, France'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'ANRS, Emerging Infectious Diseases', 'class': 'OTHER_GOV'}, 'responsibleParty': {'type': 'SPONSOR'}}}}